United Therapeutics(US:UTHR) ZACKS·2025-02-24 15:21Core Viewpoint - Analysts project that United Therapeutics (UTHR) will report quarterly earnings of $6.10 per share, reflecting a year-over-year increase of 39.9% and revenues of $725.32 million, which is an 18% increase from the same quarter last year [1]. Earnings Estimates - The consensus EPS estimate has been revised 0.5% higher in the last 30 days, indicating a collective reevaluation by analysts [2]. - Changes in earnings estimates are crucial for predicting investor reactions, with empirical studies showing a strong correlation between earnings estimate revisions and short-term stock performance [3]. Revenue Projections - Analysts estimate 'Revenues- Adcirca' at $6.10 million, a decrease of 10.3% year-over-year [5]. - The consensus for 'Revenues- Orenitram' is $109.01 million, indicating a 29.6% increase from the previous year [5]. - 'Revenues- Remodulin' is projected to reach $117.28 million, reflecting a 1.9% year-over-year increase [5]. - 'Revenues- Tyvaso' is expected to be $425.28 million, showing a significant increase of 99% from the year-ago quarter [6]. - 'Revenues- Unituxin' is projected at $59.93 million, a 10.6% increase year-over-year [6]. - 'Revenues- Rest-of-World' is estimated to reach $30.17 million, indicating a 4.7% increase from the prior year [6]. - 'Revenues- United States' is expected to be $681.36 million, reflecting a 16.3% increase from the previous year [7]. Stock Performance - Over the past month, United Therapeutics shares have recorded a return of -2.6%, compared to the Zacks S&P 500 composite's -0.5% change [7]. - Based on its Zacks Rank 4 (Sell), UTHR is expected to underperform the overall market in the upcoming period [7].